TABLE 3.
Target organ | β (mGy/MBq) | Photon (mGy/MBq) | Total (mGy/MBq) | Absorbed dose (mGy) (150 MBq) |
---|---|---|---|---|
Adrenals | 5.87E–03 | 7.62E–03 | 1.35E–02 | 2.0 |
Brain | 5.87E–03 | 2.43E–03 | 8.29E–03 | 1.2 |
Breasts | 5.87E–03 | 2.58E–03 | 8.44E–03 | 1.3 |
Gallbladder wall | 1.16E–02 | 7.99E–03 | 1.96E–02 | 2.9 |
Lower large intestine wall | 5.87E–03 | 4.68E–03 | 1.06E–02 | 1.6 |
Small intestine | 5.87E–03 | 5.24E–03 | 1.11E–02 | 1.7 |
Stomach wall | 5.87E–03 | 5.24E–03 | 1.11E–02 | 1.7 |
Upper large intestine wall | 5.87E–03 | 5.25E–03 | 1.11E–02 | 1.7 |
Heart wall | 1.48E–02 | 5.36E–03 | 2.02E–02 | 3.0 |
Kidneys | 1.96E–01 | 2.31E–02 | 2.20E–01 | 33.0 |
Liver | 3.30E–02 | 1.01E–02 | 4.31E–02 | 6.5 |
Lungs | 5.87E–03 | 3.91E–03 | 9.78E–03 | 1.5 |
Muscle | 5.87E–03 | 3.65E–03 | 9.52E–03 | 1.4 |
Ovaries | 5.87E–03 | 4.94E–03 | 1.08E–02 | 1.6 |
Pancreas | 5.87E–03 | 7.38E–03 | 1.32E–02 | 2.0 |
Red marrow | 8.07E–03 | 4.35E–03 | 1.24E–02 | 1.9 |
Osteogenic cells | 1.16E–02 | 4.04E–03 | 1.57E–02 | 2.4 |
Skin | 5.87E–03 | 2.28E–03 | 8.15E–03 | 1.2 |
Spleen | 5.26E–02 | 1.09E–02 | 6.34E–02 | 9.5 |
Testes | 5.87E–03 | 3.28E–03 | 9.14E–03 | 1.4 |
Thymus | 5.87E–03 | 3.62E–03 | 9.49E–03 | 1.4 |
Thyroid | 5.87E–03 | 3.15E–03 | 9.01E–03 | 1.4 |
Urinary bladder wall | 5.70E–02 | 1.03E–02 | 6.74E–02 | 10.1 |
Uterus | 5.87E–03 | 5.72E–03 | 1.16E–02 | 1.7 |
Salivary glands | 6.07E–02 | — | 6.07E–02 | 9.1 |
Total body | 7.88E–03 | 3.85E–03 | 1.17E–02 | 1.8 |
Effective dose coefficient (mSv/MBq) | 1.99E–02 | |||
Effective dose coefficient (mSv/MBq)* | 1.93E–02 ± 0.09E–02 | |||
Effective dose (mSv) | 3.0 |
Mean effective dose coefficient of P1–P5.